Article Text

Download PDFPDF
Vascular endothelial growth factor suppression times in patients with diabetic macular oedema treated with ranibizumab
  1. Philipp S Muether,
  2. Katharina M Droege,
  3. Sascha Fauser
  1. Department of Ophthalmology, University of Cologne, Cologne, Germany
  1. Correspondence to Dr Sascha Fauser, Department of Ophthalmology, University Hospital of Cologne, Kerpener Str. 62, Cologne 50923, Germany; Sascha.fauser{at}


Background To measure vascular endothelial growth factor (VEGF) levels in aqueous humour from patients with diabetic macular oedema (DME) treated with ranibizumab and to determine how long VEGF was suppressed.

Methods In this nonrandomised, prospective clinical study, 17 eyes of 17 patients were included in the study. A total of 110 aqueous humour samples were taken before an intravitreal ranibizumab injection in patients with DME. VEGF-A was measured by Luminex multiplex bead analysis (Luminex Inc, USA).

Results VEGF was completely suppressed in all patients after ranibizumab injections for a mean of 33.7 days (SD±5.1, range 27–42, median 34). VEGF suppression times were individually stable during the observation time of up to 16 months. There was no statistically significant difference of VEGF levels at baseline and before the beginning of a new injection series (123.6 pg/mL vs 125.1 pg/mL; p=1.0, Wilcoxon).

Conclusions Monthly ranibizumab injections lead to a complete VEGF suppression in patients with DME. The long-term stability and the range of suppression times among individuals suggest that some patients could benefit from individual injection intervals.

  • Aqueous humour
  • Drugs
  • Macula

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.